Takeuchi Hironori, Matsuno Naoto, Senuma Kayoko, Hirano Toshihiko, Yokoyama Takayoshi, Taira Shinichiro, Kihara Yu, Kuzuoka Kentaro, Konno Osamu, Jojima Yoshimaro, Mejit Abudushukur, Akashi Isao, Nakamura Yuki, Iwamoto Hitoshi, Hama Koichiro, Iwahori Tohru, Ashizawa Tatsuto, Nagao Takeshi, Toraishi Tatsunori, Okuyama Kiyoshi, Oka Kitaro, Unezaki Sakae
Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan.
Biol Pharm Bull. 2008 Jan;31(1):90-4. doi: 10.1248/bpb.31.90.
The clinical efficacy of calcineurin inhibitors administered to renal transplant patients is considered to be a strong function of the area under the concentration time curve (AUC). Interestingly, monitoring timings of blood concentrations for two similar calcineurin inhibitors, cyclosporine (CYA; Neoral) and tacrolimus (TAC; Prograf) are different. Namely, CYA blood concentration is usually monitored at 2 h after administration (C(2)) substituted for peak concentration (C(p)) and TAC at trough concentration (C(t)). In the literature, data describing such characteristics of CYA and TAC have been presented in the past. However, each of these patient groups had different backgrounds. We have attempted to examine the behavior of blood concentration curves simultaneously for both CYA and TAC by establishing controlled groups of renal transplant patients with similar clinical backgrounds. Furthermore, we have analyzed the correlation with C(p) and C(t) versus AUC implementing area under the trough level (AUTL), or area above the trough level (AATL) as new pharmacokinetic parameters, such that C(2) for CYA and C(t) for TAC have been verified using controlled clinical data. We have also found distinct differences in the pharmacokinetics between CYA and TAC with the relationships between AUC, C(p), and C(t).
给予肾移植患者钙调神经磷酸酶抑制剂的临床疗效被认为是浓度-时间曲线下面积(AUC)的一个重要函数。有趣的是,两种相似的钙调神经磷酸酶抑制剂环孢素(CYA;新山地明)和他克莫司(TAC;普乐可复)的血药浓度监测时间不同。具体而言,CYA血药浓度通常在给药后2小时(C(2))监测,以替代峰浓度(C(p)),而TAC则在谷浓度(C(t))监测。在过去的文献中,已经呈现了描述CYA和TAC这些特征的数据。然而,这些患者群体中的每一组都有不同的背景。我们试图通过建立具有相似临床背景的肾移植患者对照组,同时研究CYA和TAC的血药浓度曲线行为。此外,我们分析了C(p)和C(t)与AUC的相关性,将谷浓度水平以下面积(AUTL)或谷浓度水平以上面积(AATL)作为新的药代动力学参数,从而利用对照临床数据验证了CYA的C(2)和TAC的C(t)。我们还发现CYA和TAC在药代动力学方面存在明显差异,以及AUC、C(p)和C(t)之间的关系。